The New England journal of medicine
-
Multicenter Study
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors.
NF2-related schwannomatosis (NF2-SWN, formerly called neurofibromatosis type 2) is a tumor predisposition syndrome that is manifested by multiple vestibular schwannomas, nonvestibular schwannomas, meningiomas, and ependymomas. The condition is relentlessly progressive with no approved therapies. On the basis of preclinical activity of brigatinib (an inhibitor of multiple tyrosine kinases) in NF2-driven nonvestibular schwannoma and meningioma, data were needed on the use of brigatinib in patients with multiple types of progressive NF2-SWN tumors. ⋯ Brigatinib treatment resulted in radiographic responses in multiple tumor types and clinical benefit in a heavily pretreated cohort of patients with NF2-SWN. (Funded by the Children's Tumor Foundation and others; INTUITT-NF2 ClinicalTrials.gov number, NCT04374305.).
-
Comment Letter Case Reports
Case 6-2024: A 21-Year-Old Man with Fatigue and Night Sweats. Reply.
-
Comment Letter Case Reports
Microaxial Flow Pump in Infarct-Related Cardiogenic Shock. Reply.